OV-2295(R2) cell line

Relapse-derived HGSOC ascites cell line with acquired carboplatin resistance in a matched treatment-evolution series

Contributors

Inventor Institute
Anne-Marie Mes-Masson and Diane Provencher Centre Hospitalier de L’université de Montréal
SKU: 161774
Product description: OV-2295(R2) was established from ascites from patient 2295 after chemotherapy and forms part of the matched series with pre-treatment OV-2295 and relapse-derived TOV-2295(R). The defining study demonstrated clear acquired carboplatin resistance in OV-2295(R2), providing a clinically evolved resistant state within a same-patient longitudinal system. Used alongside the earlier OV-2295 model and TOV-2295(R), it supports comparison of pre-treatment versus post-treatment disease and of different relapse sampling sites within the same patient.
Alternate name: OV-2295(R2)
Gender: Female
CRISPR: No
Production details: Patient ascites were centrifuged and seeded in 100mm plate with OSE medium and maintained for 40 days with weekly media replacement.
Additional notes: Patient 2295 was diagnosed with ovarian cancer following imaging, ascites puncture, and partial ommentectomy. Patient was included in a clinical trial and treated with cisplatin/topotecan for the first four months following diagnosis. From months 4-7, patient received carboplatin and paclitaxel and responded well to chemotherapy initially. Three months after the end of chemotherapy however, ascites volume increased and later underwent ovarian cytoreduction. Eleven months after diagnosis, she …
Receptors of note: No
Related tools: 161773 ; 161775
Cat. #: 161774
Cancer types: Ovarian cancer
Research Fields: Cancer
Organism: Human
Tissue: Derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
Gender: Female
Morphology: Aquired resistance to carboplatin. Expresssion of tumor suppressor p53 present. Strong HER2 expression detected in protein extracts and observed in solid tissues by IHC. Spheroid formation: semi compact
Growth properties: Adherent
Primary citation: Létourneau et al. 2012. BMC Cancer. (12): 379. PMID: 22931248
Shipping conditions: Dry Ice
Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
Atmosphere: Hypoxic condition of 5%O2 and 5%CO2
References:

Tomas et al. 2023. J Ovarian Res. 11

16(1):70. PMID: 37038202 Vias et al. 2023. Elife. 11

12:e83867. PMID: 37166279 Jubelin et al. 2022. Cell Biosci. 11

12(1):155. PMID: 36089610 Canals et al. 2022. Front Oncol. 4

12:856424. PMID: 35600398

Related Tools for Cell lines

Cat. # Tool Name
161773 OV-2295 cell line Key Info View Tool
161775 TOV-2295 (R) cell line Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.